title: A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia.
abstract: We evaluated the use of dexamethasone in preterm infants to decrease morbidity associated with bronchopulmonary dysplasia in a randomized, double-blind, placebo-controlled trial. Thirty-six preterm infants (birth weight, less than or equal to 1250 g and gestational age, less than or equal to 30 weeks) who were dependent on oxygen and mechanical ventilation at two weeks of age received a 42-day course of dexamethasone (n = 13), an 18-day course of dexamethasone (n = 12), or saline placebo (n = 11). The starting dose of dexamethasone was 0.5 mg per kilogram of body weight per day, and it was progressively lowered during the period of administration. Infants in the 42-day dexamethasone group, but not those in the 18-day group, were weaned from mechanical ventilation significantly faster than control infants (medians 29, 73, and 84 days, respectively; P less than 0.05), and from supplemental oxygen (medians 65, 190, and 136 days, respectively; P less than 0.05). No clinical complications of steroid administration were noted. Follow-up of all 23 survivors at 6 and 15 months of age showed good outcome (normal neurologic examinations and Bayley Developmental Indexes greater than or equal to 84) in 7 of the 9 infants in the 42-day dexamethasone group, but in only 2 of the 9 infants in the 18-day dexamethasone group and 2 of the 5 in the placebo group (P less than 0.05). We conclude that dexamethasone therapy for 42 days improves pulmonary and neurodevelopmental outcome in very-low-birth-weight infants at high risk for bronchopulmonary dysplasia.
authors.affiliation: Department of Pediatrics, State University of New York Health Science Center, Syracuse.
authors.forename: J J
authors.initials: JJ
authors.lastname: Cummings
authors.forename: D B
authors.initials: DB
authors.lastname: D'Eugenio
authors.forename: S J
authors.initials: SJ
authors.lastname: Gross
mesh_terms: D001997:Bronchopulmonary Dysplasia / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000503:physiopathology; D008297:Male; D011897:Random Allocation; D012121:Respiration, Artificial
chemical_list: D003907:Dexamethasone